(30 April 2020)Favipiravir – early viral clearance contributed to the improvement of chest imaging on Day 14

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

https://doi.org/10.1016/j.eng.2020.03.007

In this open-label comparative controlled study of patients with COVID-19, those treated with Favipiravir (FPV) appeared to have faster viral clearance and better chest imaging change on day 14 than patients treated with LPV/RTV.  Fewer adverse events were found in the FPV arm than in the control arm. FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection.